Health

Novo Beat Eli Lilly Head-to-Head in weight loss drug showdown

CagriSema cut body weight 12.4% to tirzepatide's 9.1% in a direct phase 3 head-to-head, and Novo's stock fell anyway. The FDA rules on the drug in Q4, with Medicare already paying for the rivals and Lilly $6.5 billion deep in new pill capacity.

Vincent JiangVincent Jiangtwo-minute read
Share
The Novo Nordisk headquarters in Denmark, seen behind a blue company sign
1 / 6Slide 1 of 6
Novo Nordisk's headquarters in Denmark. Its CagriSema beat Lilly's tirzepatide in a phase 3 head-to-head trial, yet the shares fell as much as 9% on the news.

Novo−1.72% — Novo, down 1.72 percent today has spent the tirzepatide era as the smaller player: 39% of the obesity drug market to Lilly's−2.87% — Lilly, down 2.87 percent today 60% as of the first quarter 7. At its Capital Markets Day in London on 21 September 2026, Novo announced the answer it has been building.

Lilly's revenue roughly doubled in the tirzepatide era while Novo's stalled

  • Eli Lilly
  • Novo Nordisk
$0B$10B$20B$30BQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26$12BLilly leads Novo by $11.0B aquarter
Data
Eli LillyNovo Nordisk
Q3 '24$11.4B$10.5B
Q4 '24$13.5B$12B
Q1 '25$12.7B$11.3B
Q2 '25$15.6B$12.1B
Q3 '25$17.6B$11.8B
Q4 '25$19.3B$12.4B
Q1 '26$19.8B$14.9B
Q2 '26$23B$12B
Company-wide quarterly revenue in US dollars, from each company's SEC filings, rounded to $0.1B. Lilly grew from $11.4B in Q3 2024 to $23.0B in Q2 2026 while Novo went from $10.5B to $12.0B. Sources: Sharadar quarterly fundamentals, retrieved 24 September 2026.11,12

In REIMAGINE 5, a phase 3 trial putting once-weekly CagriSema 1.0/1.0 mg directly against tirzepatide 5 mg in adults with type 2 diabetes, CagriSema patients lost an estimated 12.4% of body weight at week 60 against 9.1% for tirzepatide, with non-inferior HbA1c reduction, 1.71% to 1.67% 123. In REDEFINE 9, in obesity, CagriSema delivered 21.0% weight loss against 2.0% for placebo 2.

CagriSema beat tirzepatide head-to-head and hit 21% against placebo

  • Estimate
0%5%10%15%20%25%CagriSema 1.0/1.0 mg, obesity (REDEFINE 9)21%CagriSema 1.0/1.0 mg, diabetes (REIMAGINE 5)12.4%Tirzepatide 5 mg, diabetes (REIMAGINE 5)9.1%tested at 5 mg, a third of Lilly's 15 mg ceilingPlacebo, obesity (REDEFINE 9)2%
Data
Value
CagriSema 1.0/1.0 mg, obesity (REDEFINE 9) (estimate)21%
CagriSema 1.0/1.0 mg, diabetes (REIMAGINE 5) (estimate)12.4%
Tirzepatide 5 mg, diabetes (REIMAGINE 5) (estimate)9.1%
Placebo, obesity (REDEFINE 9) (estimate)2%
Estimated average change in body weight by trial arm, percent. REIMAGINE 5 measured week 60 in adults with type 2 diabetes; REDEFINE 9 measured week 68 in adults with overweight or obesity; all figures based on the efficacy estimand. Sources: Novo Nordisk release, 21 September 2026; MPR, 21 September 2026.1,2,3

The stock fell anyway

The win did not lift the shares. They fell as much as 9% on Monday as analysts pressed Novo on pricing power and dealmaking ahead of semaglutide patent expiries in the early 2030s 4, extending a year-to-date decline of 21% 5. The fall suggests the market was trading the 2035 target of DKK 150 billion in pipeline sales, about $23 billion, and a CagriSema launch planned for early next year 4, not Monday's numbers.

Novo Nordisk chief executive Mike Doustdar speaking on stage
Novo Nordisk chief executive Mike Doustdar. His Capital Markets Day in London paired the CagriSema head-to-head win with 2035 targets the market did not buy.Canyak1982

The comparator was 5 mg, not Lilly's ceiling

The fight inside the data is the dose. REIMAGINE 5 ran tirzepatide at 5 mg; the approved Zepbound and Mounjaro label climbs in 2.5 mg steps to a 15 mg maximum 6. Novo's release anticipates the objection, arguing treatment is individualised and "not all patients receive or remain on the highest available dose" 2.

Every headline figure also rests on the efficacy estimand, per the release's footnote 2. Lilly's strongest dose never entered the ring.

Medicare is paying while Lilly builds

Since 1 July 2026, Medicare's Bridge program has sold obesity GLP-1s to seniors at $50 a month through 2027: Wegovy's pill and injection, Zepbound's KwikPen and Lilly's Foundayo 7. KFF counts 3.8 million eligible seniors, and a Medicare bill of $1.3 billion to $3.3 billion if 10% to 25% of them participate 8.

CagriSema reaches that list only if the FDA approves the December 2025 weight-management filing, a decision due in Q4 2. The day Novo read out, Lilly broke ground on a $6.5 billion Houston plant to make Foundayo 910, a bet The Inference framed as a hedge on a pill shift Novo dominates.

The Q4 verdict is the tell

Watch the FDA decision, then the formularies. If an approved CagriSema lands on public money at a ranked price, Lilly has just poured $6.5 billion into capacity for a race it can now lose on data.

Get Health by email, free

AI in medicine, pharma and biotech. In our daily email, every weekday.

Loading LLY

Reader comments

0 comments

    More in Health

    All in this topic →

    Health

    Eli Lilly Agreed to Buy Calytrix Bio for Up to $1.5 Billion, Its Latest Deal in a $32 Billion Year

    A $32 billion acquisition year rests on an $11 billion quarterly cash engine, but the deal headlines are "up to" figures and the balance sheet is already thinning. Whose money moves: anyone holding LLY at 31 times forward earnings into December 7 and January.

    Health

    GE HealthCare's manganese MRI agent matched gadolinium, a route past China's rare earths

    About 65 million contrast-enhanced MRI scans a year run on gadolinium, a rare earth whose export China licenses. A manganese substitute that matched the incumbent in GE HealthCare's Phase 2 trial opens a route off that chain for the company's highest-margin segment, if Phase 3 holds.

    Health

    Abridge lost AI scribing to Microsoft and Epic; its next market has a $100 million price from Wolters Kluwer

    Microsoft and Epic took two of every three new AI-scribe dollars this year, and Abridge, which built that market, is selling what comes after the note. The decision-support category it is moving into just got a public price, Wolters Kluwer's $100 million AgileMD deal, and that price is what Abridge's $6.69 billion private mark has to outrun.

    Health

    CMS's CRUSH rule reaches past Medicare into Molina's $42 billion Medicaid book

    The November 18 rout priced the proposal as a UnitedHealth-Humana Medicare bill. Molina is leaving that business, so for it the rule's weight falls on the Medicaid audit duties covering the $42 billion premium book that carries its $9.50 2027 earnings framework.

    Health

    AstraZeneca commits $200 million to Tempus AI through 2031 but can walk away for the shortfall

    A five-year, $200 million renewal from AstraZeneca gives Tempus AI a revenue floor it can book, filed days before a shareholder vote on a stock-funded acquisition, but the contract lets the drugmaker quit early by paying only the shortfall.

    Health

    OpenEvidence CEO tells medical students to take paper exams as OpenAI and Anthropic give doctors AI free

    Daniel Nadler built a $15 billion company on giving doctors AI answers free. On Monday he warned the doctors still training on his tool that AI erodes the skill that makes an answer worth having.

    Subscribe to TheInference for free